ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and currently in Phase II for Liver Cancer. According to GlobalData, Phase II drugs for Liver Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ICTCAR-028’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ICTCAR-028 overview
ICTCAR-028 is under development for the treatment of solid tumors including pancreatic cancer, gastric cancer, esophageal cancer, liver cancer, gastroesophageal (GE) junction carcinomas, colorectal cancer and hematological tumor. The therapeutic candidate constitutes chimeric antigen receptor (CAR) T cells. It is developed based on CAR-T technology. It is administered through parenteral route.
Innovative Cellular Therapeutics overview
Innovative Cellular Therapeutics (ICT) is a biotechnology company that disovers and develops cellular immunotherapies for the treatment of cancer. ICT is headquartered in Shanghai, China.
For a complete picture of ICTCAR-028’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
